State board outlines 503B outsourcing inspection program, warns of scale and cGMP expectations
Get AI-powered insights, summaries, and transcripts
Subscribe
Summary
Supervising inspector JK Fujimoto told the Enforcement & Compounding Committee that 503B outsourcing facilities operate at industrial scale, are subject to federal CGMP standards (21 CFR parts 210 and 211) and FDA risk-based inspection, and that California—s board conducts multi-day annual licensure inspections to supplement federal oversight. The
Supervising inspector JK Fujimoto of the California State Board of Pharmacy told the committee on Oct. 16 that 503B outsourcing facilities differ from traditional compounding pharmacies in scale, regulation and risk.
"Outsourcing facilities are typically not open to the public," Fujimoto said, describing sites that can range from tens of thousands to more than 750,000 square feet, with specialized warehousing, laboratories, HVAC and water-for-injection systems. He said products from 503B firms can be distributed nationwide and often in case or pallet quantities.
The distinction matters because 503B facilities must comply with current good manufacturing practices under federal law. "They must follow 21 CFR parts 210 and 211," Fujimoto said, adding that FDA inspects on a risk-based schedule and firms must report certain adverse events and product catalogs to the agency.
Fujimoto explained how California—s program supplements federal oversight. The board licenses outsourcing facilities under state law (SB1193) and performs licensure inspections that "tend to be much longer in duration and scope" than routine pharmacy inspections—typically about three business days and conducted by two inspectors, he said. State inspectors request large datasets in advance and review records for weeks to assess complex quality systems.
Committee members and public commenters praised the program. Licensing member Renee Barker said California—s inspections are used by other entities when assessing facilities, and public commenter Steven Gray recalled an early, large-scale compounding operation and urged continued emphasis on sterility and batch testing.
Fujimoto listed key program demographics and operational figures: as of August 2025, 92 outsourcing facilities were registered with FDA nationwide; three licensed locations were in California and 20 were licensed outside the state. He said many 2024–25 registrations represented preoperational sites and that inspections demand specialized staff with pharmaceutical manufacturing expertise.
Staff identified program challenges: inspections require significant time and travel, many licensed sites are out of state, the volume and complexity of records are large, and coordinating asynchronous regulatory activity (FDA, DEA, other states) is resource intensive. The board has adjusted fees, trained a specialized inspector team, and requests datasets 6–8 weeks before inspections to improve review efficiency.
Fujimoto suggested some state statutes could be harmonized with FDA registration requirements (for example, address requirements) and asked the committee to consider those changes in future rulemaking. Chair Maria Serpa thanked Fujimoto and commended the inspection team for its work.
Public commenters at the meeting urged continued transparency and education about the difference between 503A and 503B products and the degree of testing and quality assurance that outsourcing facilities perform.
Looking ahead, Fujimoto said the program will maintain a high level of expectation for compounded products supplied to California patients and continue coordination with other states and the FDA, while the board considers statutory alignment to streamline regulation.